BREAKING NEWS 

Russia has announced the official commencement of human trials for its personalized mRNA melanoma vaccine, with rollouts expected in September–October 2025 at leading Moscow cancer centers.

Based on AI-powered tumor sequencing, each vaccine is custom-designed and manufactured in just one week. 

And there’s more—this immunotherapy will be free for eligible Russian citizens, thanks to state funding (~300,000 rubles/dose).

Supported by promising preclinical results, this initiative could influence future cancer vaccine strategies globally.

Stay tuned as Russia spearheads this groundbreaking leap in oncology. 

Leave a Reply

Your email address will not be published. Required fields are marked *